Omiganan

Antimicrobial Peptide / Topical

Also known as: MBI-226, Omiganan pentahydrochloride, MX-594AN

Synthetic Antimicrobial PeptidesResearch phase: Phase 3Regulatory: Not approved. Completed Phase 3 trials without FDA approval.

Mechanism

Omiganan is a synthetic antimicrobial peptide based on bovine indolicidin, developed as a topical antiseptic for preventing catheter infections and treating skin conditions.

Technical detail

Omiganan is a 12-amino acid synthetic analog of indolicidin with enhanced antimicrobial potency and reduced hemolytic activity. It disrupts bacterial membranes through electrostatic interaction. Phase 3 trials for catheter site infection prevention narrowly missed primary endpoints. Also studied topically for rosacea and acne.

Evidence

Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial
Rousel J et al. (2023) — International Journal of Molecular Sciences — PMID: 37762625
Randomized proof-of-concept trial compared topical omiganan with ketoconazole and placebo in mild-to-moderate facial seborrheic dermatitis, adding early comparative human evidence for dermatologic use.
moderate
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial
Niemeyer-van der Kolk T et al. (2022) — Journal of the American Academy of Dermatology — PMID: 33010325
Topical omiganan given twice daily for up to 28 days improved cutaneous dysbiosis in mild-to-moderate atopic dermatitis but did not deliver meaningful clinical symptom improvement, making it a limited-efficacy human signal.
moderate

Build a personalized protocol with Omiganan →